{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '64', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '7. Has a known history of human immunodeficiency virus (HIV) infection; HIV testing is', 'not required unless mandated by the local health authority.', '8. Has a history of (noninfectious) pneumonitis that required systemic steroids or current', 'pneumonitis/interstitia lung disease.', '9. Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]', 'reactive or hepatitis B virus [HBV]-DNA detected) or known active hepatitis C virus', '(HCV, defined as HCV-RNA [qualitative] detected or HCV antibody reactive, if', 'HCV-RNA is not the local SOC) infection.', '-', 'Note: No testing for hepatitis B and hepatitis C is required unless mandated by the', 'local health authority.', '10. Has a history of a gastrointestinal condition or procedure that in the opinion of the', 'investigator may affect oral study drug absorption.', '11. Has significant cardiovascular impairment within 12 months of the first dose of study', 'intervention, such as a history of congestive heart failure greater than New York Heart', 'Association Class II, unstable angina, myocardial infarction, cerebrovascular accident', '(CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.', '12. Has not recovered adequately from any toxicity and/or complications from major surgery', 'before starting therapy.', '13. Has a known history of active tuberculosis (TB).', '14. Has an active infection requiring systemic therapy.', '15. Has a known psychiatric or substance abuse disorder that would interfere with the', \"participant's cooperation for the requirements of the study.\", '16. Previously had a severe hypersensitivity reaction to treatment with an mAb or has a', 'known sensitivity or intolerance to any component of lenvatinib or pembrolizumab.', '17. WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of', 'study intervention. If the urine test is positive or cannot be confirmed as negative, a', 'serum pregnancy test will be required.', 'Note: If more than 24 hours have elapsed between the screening pregnancy test and the', 'first dose of study intervention, another pregnancy test (urine or serum) must be', 'performed and must be negative for the participant to start receiving study intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '65', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Prior/Concomitant Therapy', '18. Has received prior systemic chemotherapy or other targeted or biological antineoplastic', 'therapy for their metastatic NSCLC.', 'Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant', 'or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was', 'completed at least 6 months before the diagnosis of metastatic NSCLC.', '19. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an', 'agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,', 'OX 40, CD137) or has received lenvatinib as monotherapy or in combination with', 'anti-PD-1 agents.', '20. Has received radiotherapy within 14 days before the first dose of study intervention or', 'received lung radiation therapy of>30 Gy within 6 months before the first dose of study', 'intervention.', 'Note: Participants must have recovered from all radiation-related toxicities to Grade 1 or', 'less, not require corticosteroids, and not have had radiation pneumonitis.', '21. Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive', 'therapy within 7 days before the first dose of study intervention.', '22. Is receiving systemic steroid therapy (doses exceeding 10 mg daily of prednisone', 'equivalent) within 7 days before the first dose of study intervention.', '23. Has received a live or attenuated vaccine within 30 days before the first dose of study', 'intervention. Note: Killed vaccines are allowed.', 'Prior/Concurrent Clinical Study Experience', 'Not applicable.', 'Diagnostic Assessments', '24. Participants with proteinuria > -1+ on urine dipstick testing/urinalysis will undergo', '24-hour urine collection for quantitative assessment of proteinuria. Participants with', 'urine protein >1 g/24 hours will be ineligible.', 'Prolongation of QTc interval to >480 ms and/or left ventricular ejection fraction (LVEF)', 'below the institutional normal range as determined by a multigated acquisition scan', '(MUGA) or echocardiogram (ECHO).', 'Other Exclusions', '25. Has a history or current evidence of any condition, therapy, or laboratory abnormality', \"that might confound the results of the study or interfere with the participant's ability to\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}